THX Pharma
ALTHX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €2,283 | €296 | €415 | €1 |
| % Growth | 670.5% | -28.6% | 68,819.9% | – |
| Cost of Goods Sold | €2,617 | €4,935 | €332 | €8,823 |
| Gross Profit | -€334 | -€4,639 | €83 | -€8,822 |
| % Margin | -14.6% | -1,565.4% | 20% | -1,465,443.5% |
| R&D Expenses | €2,673 | €7,543 | €3,924 | €5,554 |
| G&A Expenses | €2,091 | €2,599 | €7,022 | €591 |
| SG&A Expenses | €2,147 | €2,702 | €1,574 | €678 |
| Sales & Mktg Exp. | €56 | €103 | €149 | €87 |
| Other Operating Expenses | -€2,527 | -€7,240 | €427 | -€5,542 |
| Operating Expenses | €2,293 | €3,005 | €5,925 | €690 |
| Operating Income | -€4,810 | -€7,644 | -€6,257 | -€9,513 |
| % Margin | -210.7% | -2,579.4% | -1,508.1% | -1,580,201% |
| Other Income/Exp. Net | €2,277 | €14 | -€930 | -€396 |
| Pre-Tax Income | -€2,533 | -€7,630 | -€7,186 | -€9,909 |
| Tax Expense | €768 | -€802 | -€619 | -€1,758 |
| Net Income | -€1,765 | -€6,828 | -€6,567 | -€8,150 |
| % Margin | -77.3% | -2,304.2% | -1,582.8% | -1,353,889.4% |
| EPS | -0.21 | -0.88 | -1.24 | -1.66 |
| % Growth | 76.1% | 29% | 25.3% | – |
| EPS Diluted | -0.21 | -0.88 | -1.23 | -1.66 |
| Weighted Avg Shares Out | 8,537 | 7,759 | 5,315 | 4,924 |
| Weighted Avg Shares Out Dil | 8,537 | 7,759 | 5,346 | 4,924 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €82 | €109 |
| Interest Expense | €153 | €84 | €158 | €33 |
| Depreciation & Amortization | €96 | €256 | €332 | €1,204 |
| EBITDA | -€2,530 | -€7,387 | -€5,925 | -€8,672 |
| % Margin | -110.8% | -2,492.9% | -1,428.1% | -1,440,519.1% |